A case of EBV-associated lymphoproliferative disease following high-dose therapy and CD34-purified autologous peripheral blood progenitor cell transplantation

Bone Marrow Transplantation

Volumn 22, Issue 3, 1998, Pages 307-309

  Peniket, A J ^a   Perry, A R ^a   Williams, C D ^a   MacMillan, A ^a   Watts, M J ^a   Isaacson, P G ^b   Goldstone, A H ^a   Linch, D C ^a  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b MOUNT VERNON HOSPITAL   (United Kingdom)

Author keywords

CD34 selection; EBV associated lymphoma; Myeloma

Indexed keywords

CD34 ANTIGEN;

ADULT; ARTICLE; CASE REPORT; CELL SELECTION; EPSTEIN BARR VIRUS; FATALITY; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN CELL; LYMPHOPROLIFERATIVE DISEASE; MULTIPLE MYELOMA; OPPORTUNISTIC INFECTION; PRIORITY JOURNAL; T LYMPHOCYTE;

EID: 0031857596     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1701335     Document Type: Article

References (30)

1. Beyer J, Schwella N, Zingsem J et al. Hematopoietic rescue after high dose chemotherapy using autologous peripheral blood progenitor cells or bone marrow: a randomized comparison. J Clin Oncol 1995; 13: 1328-1335.
2. Schmitz N, Linch DC, Dreger P et al. Randomised trial of filgrastim mobilised peripheral blood progenitor cell transplant versus autologous bone marrow transplantation in lymphoma patients. Lancet 1996; 347: 353-357.
3. Smith TJ, Hillner BE, Schmilz N et al. Economic analysis of a randomised clinical trial to compare filgrastim-mobilised PBSC transplantalion and ABMT in patients with Hodgkin's disease and non-Hodgkin's lymphoma. J Clin Oncol 1997; 15: 5-10.
4. Kessinger A, Armitage JO, Landmark JD et al. Autologous peripheral hematopoietic stem cell transplantation restores hematopoietic function following myeloablative therapy. Blood 1988; 71: 723-727.
5. Brugger W, Bross KJ, Glatt M et al. Mobilization of tumor cells and hematopoietic progenitor cells into peripheral blood of patients with solid tumors. Blood 1994; 83: 623-625.
6. + peripheral blood progenitor cells after high dose chemotherapy for patients with advanced multiple myeloma. Blood 1995; 86: 390-397.
7. + marrow cells in patients with breast cancer or neuroblastoma. Blood 1991; 77: 1717-1722.
8. Cagnoni PJ, Shpall EJ. Mobilisation and selection of CD34-positive hematopoietic progenitors. Blood Rev 1996; 10: 1-7.
9. + enriched peripheral blood and bone marrow cells contribute to long-term engraftment after autologous transplantation. Blood 1995; 85: 3048-3057.
10. + progenitor cells from matched related donors. Bone Marrow Transplant 1996; 18: 1081-1086.
11. + cell purification: experience of 71 immunoaffinity column procedures. Bone Marrow Transplant 1997; 20: 157-162.
12. Philip T, Guglielmi C, Hagenbeek A et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy sensitive non Hodgkin's lymphoma. New Engl J Med 1995; 333: 1540-1545.
13. Linch DC, Winfield D, Goldstone AH et al. Dose intensification with autologous bone marrow transplantation is effective in relapsed and resistant Hodgkin's disease: results of a BNLI randomized trial. Lancet 1993; 341: 138-142.
14. Attal M, Harousseau JL, Stoppa AM et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. New Engl J Med 1996; 335: 91-97.
15. Vescio RA, Hong CH, Cao J et al. The hematopoietic stem cell antigen, CD34, is not expressed on the malignant cells in multiple myeloma. Blood 1994; 84: 3283-3290.
16. Brenner MK, Rill DR, Moen RC et al. Gene-marking to trace the origin of relapse after autologous bone-marrow transplantation. Lancet 1993; 341: 85-86.
17. Nadler LM, Takvorian T, Botnick L et al. Anti-B1 monoclonal antibody and complement treatment in autologous bone-marrow transplantation for relapsed B-cell non-Hodgkin's lymphoma. Lancet 1984; 2: 427-431.
18. Treleaven JG, Gibson FM, Ugelstad J et al. Removal of neuroblastoma cells from bone marrow with monoclonal antibodies conjugated to magnetic microspheres. Lancet 1984; 1: 70-73.
19. Civin CI, Strauss LC, Brovall C et al. Antigenic analysis of hematopoiesis. III. A hematopoietic progenitor cell surface antigen defined by a monoclonal antibody raised against KG-1a cells. J Immunol 1984; 133: 157-165.
20. + marrow cells engraft lethally irradiated baboons. J Clin Invest 1988; 81: 951-955.
21. Watts M, Jones HM, Sullivan AM et al. Accessory cells do not contribute to G-CSF or IL-6 production nor to rapid haematological recovery following peripheral blood stem cell transplantation. Br J Haematol 1995; 91: 767-772.
22. Dreger P, Viehmann K, Steinmann J et al. G-CSF mobilized peripheral blood progenitor cells for allogeneic transplantation: comparison of T-cell depletion stratagies using different CD34+ selection systems or CAMPATH-1. Exp Hematol 1995; 23: 147-154.
23. + purified autologous PBSC transplantation in patients with multiple myeloma. Blood 1997; 90: (Suppl. 2): 10 (Abstr. 4464).
24. Linch DC, Knott LJ, Thomas R et al. T cell regeneration after autologous and allogeneic bone marrow transplantation. Br J Haematol 1983; 53: 451-457.
25. Roberts MM, To LB, Gillis D et al. Immune reconstitution following peripheral blood stem cell transplantation, autologous bone marrow transplantation and allogeneic bone marrow transplantation. Bone Marrow Transplant 1993; 12: 469-475.
26. Talmadge JE, Reed E, Ino K et al. Rapid immunologic reconstitution following transplantation with mobilized peripheral blood stem cells as compared to bone marrow. Bone Marrow Transplant 1997; 19: 161-172.
27. + enriched peripheral stem cells. Ann Hematol 1996; 73 (Suppl. 2): 165 (Abstr. 657).
28. Nachbaur D, Kropshoter G, Feichtinger H et al. Cryptosporidiosis after CD34-selected autologous peripheral blood stem cell transplantation (PBSCT). Treatment with paromomycin, azithromycin and recombinant human interleukin-2. Bone Marrow Transplant 1997; 19: 1261-1263.
29. Zutter MM, Martin PJ, Sale GE et al. Epstein-Barr virus associated B cell lymphoproliferation after bone marrow transplantation. Blood 1988; 72: 520-529.
30. Papadopoulos EB, Ladanyi M, Emanuel D et al. Infusions of donor leukocytes to treat Epstein-Barr virus-associated lymphoproliferative disorders after allogeneic bone marrow transplantation. New Engl J Med 1994; 330: 1185-1191.